Eksigent Continues European Expansion with new Distribution Agreement in Benelux
News Mar 07, 2007
Eksigent has announced a new distribution agreement with Separations Analytical Instruments BV, based in The Netherlands. The agreement covers sales of Eksigent’s NanoLC™ HPLC product line in the Benelux region.
“Our NanoLC platform for proteomics applications has been well received in the U.S. biotech and pharmaceutical industries as well as the academic community,” commented David Weber, Eksigent’s President and CEO. “We have now expanded our marketing and management staff and we’re well-positioned to serve the European academic, biotech and pharmaceutical markets.”
Separations Analytical Instruments, founded in 1989, specializes in sales and service of HPLC and online SPE systems, representing a range of US and European-based manufacturers. The company serves pharmaceutical, life science and environmental customers with special emphasis on high-throughput applications.
“We are delighted to represent the Eksigent NanoLC product line,” commented Rein Reitsma, Sales Manager for Separations Analytical. “Eksigent systems are the most innovative and reliable NanoLC products we can offer to our customers in the Benelux region.”
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.